Company and Industry Overview * **Company**: Pfizer Inc. (NYSE:PFE) * **Industry**: Pharmaceuticals, Biotechnology Key Points and Arguments 1. **2024 Financial Guidance Reaffirmed**: Pfizer reaffirmed its full-year 2024 financial guidance, expecting revenues in the range of $61 billion to $64 billion and adjusted diluted earnings per share in the range of $2.75 to $2.95 [16]. 2. **2025 Financial Guidance**: Pfizer provided guidance for 2025, anticipating revenues in the range of $61 billion to $64 billion and adjusted diluted earnings per share in the range of $2.80 to $3.00 per share [19]. 3. **Revenue Growth**: Pfizer expects operational revenue growth of approximately flat to up 5% in 2025, driven by the growth of its oncology and non-COVID vaccine products [19]. 4. **Adjusted Diluted Earnings Per Share Growth**: Pfizer expects adjusted diluted earnings per share to grow operationally by approximately 10% to 18% in 2025, reflecting an operating margin expansion of over 250 basis points versus 2024 [19]. 5. **COVID-19 Products**: Pfizer expects its COVID-19 products, Comirnaty and Paxlovid, to contribute to stable revenue in 2025, with both maintaining their market shares with stable pricing [20]. 6. **Oncology**: Pfizer expects its oncology products, such as Padcev, Lorbrena, and Ibrance, to contribute significantly to growth in the later part of the decade [24]. 7. **Non-COVID Vaccine Products**: Pfizer expects its non-COVID vaccine products, such as Abrysvo and Prevnar, to remain key contributors to its business [22]. 8. **Cost Reduction**: Pfizer achieved its goal of $4 billion in net cost savings by the end of 2024 and expects an additional $500 million in net cost savings in 2025 [11]. 9. **Capital Allocation**: Pfizer remains committed to maintaining and growing its dividend, investing in its business, and de-leveraging its balance sheet [31]. Other Important Content * **Seagen Acquisition**: Pfizer highlighted the successful integration of Seagen and the positive impact of the acquisition on its oncology portfolio [8]. * **Pipeline**: Pfizer discussed its robust pipeline, including several Phase 3 studies and potential new products in various therapeutic areas [9]. * **R&D Leadership**: Pfizer announced the appointment of Dr. Chris Boshoff as its Chief Scientific Officer and President of R&D [9]. * **Capital Return**: Pfizer plans to continue monetizing its stake in Haleon over time, considering its cash flow requirements and future market conditions [31]. * **Drug Pricing**: Pfizer discussed the impact of the IRA Medicare Part D redesign on its revenue and its commitment to transparency and passing savings to patients [53].

Group 1 - Pfizer affirmed its full-year 2024 projections, expecting revenue between $61 billion and $64 billion for both 2024 and 2025, with adjusted earnings per share (EPS) projected to grow in 2025 [1][2][3] - For 2024, adjusted EPS is projected to be between $2.75 and $2.95, aligning with analyst estimates of $63.01 billion in revenue and $2.93 EPS [2][3] - Pfizer successfully met its cost-cutting goal of $4 billion by the end of 2024, with an additional $500 million in savings expected over the next year [4][5] Group 2 - Pfizer's shares rose by 4.5% following the announcement, although they remain down approximately 8% for the year [6] - The company has returned to year-over-year revenue growth in its two most recent quarters for the first time since the peak of COVID vaccine sales [1][4]

Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today. The former's 2025 profit outlook came in above expectations, and the latter's drug with Sanofi (SNY) met the main goal of a mid-stage trial of being an effective treatment for Crohn's disease and ulcerative colitis. PFE was last seen up 3.7% at $26.18, chipping away at its 12.9% year-to-date deficit. A floor at $25 contained the equity's most recent pullback, while above the 40-day moving avera ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers a wide range of sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in major cities such as London, New York, and Sydney [2] Group 2 - The company emphasizes the use of technology to enhance workflows and improve content production [4] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.For 2025, Pfizer expects revenue from COVID-19 products to remain consistent with 2024, excluding approximately $1.2 billion in one-time Paxlovid revenue recognized in 2024.The guidance accounts for an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Pa ...

Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.Pfizer highlighted several factors affecting its 2024 EPS that won’t carry over to 2025.The 2024 EPS includ ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE, ABBV e ...

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue. But it's important to note that you can turn to these players for growth too.Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these ...

With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.There's no evidence that Pfizer is about to change i ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, added 1.77%.The the stock of drugmaker has fallen by 2.37% in the past month, leading the Medical sector's loss of 4.06% and undershooting the S&P 500's gain of 0.8%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upco ...